Acrivon Therapeutics, Inc.
NASDAQThe most striking signal heading into ACRV's May 15 results is not in the lending market or the options chain — it is in the ownership table. RA Capital Management bought 3.9 million shares on April 22 at $1.80, adding $7 million in a single transaction that lifted its stake to nearly 29% of the company. That is not a passive index rebalance. RA Capital is a specialist…
Snapshot as of 14 May 2026
The most striking signal heading into ACRV's May 15 results is not in the lending market or the options chain — it is in the ownership table. RA Capital Management bought 3.9 million shares on April 22 at $1.80, adding…
Acrivon Therapeutics heads into its May 15 Q1 earnings call carrying two competing stories: a major institutional backer just bought $7 million worth of stock at the open, while short sellers are quietly adding to a…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ACRV — free to start on ORTEX.
Sign up for free →Open ACRV on ORTEX